Clinical trials: Neoadjuvant Radiotherapy
Adenocarcinoma of the Pancreas, Pancreas Cancer
Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
Standard treatment for newly diagnosed operable pancreatic cancer usually involves undergoing surgery first and then receiving chemotherapy with or without radiation therapy.
- Trial name
- NCT03778879
- Testing
- CCX872-B
- Where
- United States
- Sponsor
- Alan Katz
Esophageal Neoplasms, Carcinoma, Squamous Cell
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
To study the safety and feasibility of stereotactic radiation dose escalation following neoadjuvant chemotherapy with concurrent conventionally fractionated radiation, by evaluating the acute and late toxicity of treatment.
- Conditions
- Esophageal Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00368329
- Testing
- Capecitabine (Xeloda), [18-F] Fluorodeoxyglucose (FDG), 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Brain Metastasis
IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy
This research is being done to determine if a short course of Chloroquine (five weeks) before, during and after whole brain radiation therapy (WBRT) will improve the overall survival of subjects being treated for brain metastases.
- Trial name
- NCT01727531
- Testing
- Chloroquine diphosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Main Line Health
HER2 Positive Esophagogastric Cancer
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
With improvements in response rate and survival seen for HER2 positive patients treated with HER2 blockade in the metastatic setting, the use of HER2 blockade in the neoadjuvant setting to increase antitumor effect shows promise.
- Trial name
- NCT01769508
- Testing
- 5-Fluorouracil, Oxaliplatin, Lapatinib
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- SCRI Development Innovations, LLC
Head and Neck Neoplasms
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in…
- Trial name
- NCT03765918
- Testing
- Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray
- Where
- 192 sites in United States, Argentina and 22 more
- Volunteers
- 714 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00814619
- Testing
- panitumumab, capecitabine, therapeutic conventional surgery
- Where
- 24 sites in Hungary, Switzerland
- Volunteers
- 68 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy
This study evaluates whether radiotherapy can safely be omitted in breast cancer patients with T1-2N0 tumors who achieve a pathologic complete response after neoadjuvant systemic therapy and breast-conserving surgery
- Trial name
- NCT05416164
- Testing
- Omission of radiotherapy
- Where
- Netherlands
- Volunteers
- 595 people
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer (CRC)
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
This is a prospective, open-label, randomized, parallel-group phase II trial evaluating the efficacy and safety of a low-dose radiotherapy sensitization strategy combined with a PD-1 antibody (pucotenlimab) and CAPEOX as…
- Trial name
- NCT07448142
- Testing
- Low-dose radiotherapy, Pucotenlimab, CAPEOX/XELOX
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Rectal Neoplasm Malignant
Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer
Background: Colorectal cancer is the leading cause of cancer-related deaths in Taiwan, with rectal cancer accounting for approximately 27% of all cases.
- Trial name
- NCT06831669
- Testing
- Collecting biospecimens
- Where
- Taiwan
- Volunteers
- 250 people
- Sponsor
- Chang Gung Memorial Hospital
Pancreatic Cancer Stage II, Pancreatic Cancer Stage III
Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)
This study is for patients with locally advanced pancreatic cancer (cancer that involves the local blood vessels so it cannot be removed without cutting major blood vessels) that cannot be treated with surgery.
- Trial name
- NCT01065870
- Testing
- Neoadjuvant gemcitabine, capecitabine, and docetaxel, Gemcitabine, capecitabine, docetaxel followed by radiotherapy
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Columbia University
RECTAL CANCER
Neoadjuvant Radiotherapy Followed by Transanal Endoscopic Microsurgery for T1-T2 Extraperitoneal Rectal Cancer
Objective: Recent randomized and non-randomized studies suggest that neoadjuvant radiotherapy followed by Transanal Endoscopic Microsurgery (TEM) show comparative results to abdominal resection in pT2 extraperitoneal cancer.
- Trial name
- NERATEM (NCT02127645)
- Testing
- SRT-TEM, LRT-TEM, Transanal Endoscopic Microsurgery (TEM)
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- European Association for Endoscopic Surgery
Soft Tissue Sarcoma
Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma
This research is being done with the aim of developing a more effective treatment than standard radiotherapy and surgery alone. Although standard treatment is frequently successful, some patients do not respond well to this…
- Trial name
- SUNXRT (NCT00753727)
- Testing
- Sunitinib malate, Radiotherapy
- Where
- Australia
- Volunteers
- 26 people
- Sponsor
- Australasian Sarcoma Study Group
Breast Cancer Invasive
Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy
The primary aim is to evaluate the efficacy of neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy in patients with triple-negative breast cancer, with the endpoint being the pCR rate-defined as the…
- Trial name
- NCT06691594
- Testing
- neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Soft Tissue Sarcoma of the Extremity
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and…
- Trial name
- SU2C-SARC032 (NCT03092323)
- Testing
- Pembrolizumab
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 126 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Pancreatic Cancer
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation…
- Trial name
- NCT03161379
- Testing
- Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Rectal Cancer
Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer
In the treatment of locally advanced rectal cancer, the short-term and long-term efficacy of the traditional sandwich regimen has not reached satisfactory efficacy.
- Trial name
- NCT05228431
- Testing
- XELOX, Capecitabine monotherapy, Radiation
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Zhen-Hai Lu
Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy
Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma
Esophageal cancer is one of the most common cancers worldwide, while more than half new cases and deaths occurred in China. Surgery is the main curative treatment for this disease, the 5-year survival of EC remains poor, since…
- Conditions
- Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy, Surgery
- Trial name
- Neo-DRATEC (NCT03381651)
- Testing
- Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation, Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation
- Where
- 2 sites in China
- Volunteers
- 147 people
- Sponsor
- Zhejiang Cancer Hospital
Rectal Neoplasm
Validate the Dosimetric Parameters That Correlate With Acute Hematologic Toxicity (HT) in Patients With Rectal Cancer
The purpose of this study is to validate the dosimetric parameters that correlate with acute hematologic toxicity (HT) in patients with rectal cancer treated with neoadjuvant chemoradiotherapy.
- Trial name
- NCT02630056
- Volunteers
- 90 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Cancer
Exploring the Predictive Effect of Intestinal and Oral Microbiota on the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy for Locally Advanced Rectal Cancer Based on Machine Learning
This study is a one-year, observational, prospective cohort study. For enrolled patients with newly diagnosed locally advanced rectal cancer, the treatment plan will be decided by the physician based on the 2022 NCCN Rectal…
- Trial name
- NCT07346729
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Pancreatic Cancer
Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer
Standard chemoradiation, followed by surgery are standard treatment plan for patients suffering from pancreatic adenocarcinoma. Due to damage to the surrounding healthy tissue caused by standard radiation, this study uses a new…
- Trial name
- NCT04452357
- Testing
- PLDR
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fox Chase Cancer Center